Neola Medical

1.12 SEK

-2.62 %

Less than 1K followers

NEOLA

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-2.62 %

-33.83 %

-52.15 %

-51.94 %

-44.80 %

-49.32 %

-24.41 %

-71.36 %

-79.91 %

Neola Medical operates in the medical technology sector. The company focuses on neonatal care, where it develops medical equipment. Examples of products that the company provides to the healthcare sector include technical monitoring and follow-up of lung capacity in premature infants. In addition to the main product, ancillary products and disposables are offered. The largest operations are found in the Nordic market. Neola Medical was founded in 2016 and is headquartered in Sweden.

Market cap

86.91M SEK

Turnover

3.35 SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

12.2

2026

Annual report '25

19.5

2026

Interim report Q1'26

All

Press releases

3rd party

ShowingAll content types

Press release12/2/2025, 6:00 AM

Neola Medical granted U.S. patent for disposable probes, strengthening future revenue model in target market

Press release11/13/2025, 6:00 AM

Neola Medical granted Patent in China for reducing optical noise in lung monitoring measurements

Press release11/7/2025, 7:37 AM

Redeye: Neola Medical (Q3 Review) - Revised timeline

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/4/2025, 5:57 PM

Neola Medical Q3 Report 2025 – Progressing toward completion of Swedish clinical pilot study and strengthening leadership team

Regulatory press release11/4/2025, 5:53 PM

Revised Timeline Announced as Clinical Pilot Study Indicates Robust Safety and Need for Optimization of Neola®

Press release10/16/2025, 6:00 AM

Neola Medical Strengthens Global IP Portfolio with New Patents Granted in both the U.S. and China for Medical Device Neola®

Press release10/1/2025, 5:00 AM

Neola Medical’s CEO highlights recent progress in autumn 2025 investor letter

Regulatory press release9/25/2025, 5:20 AM

Neola Medical strengthens leadership team with appointment of Clinical Director

Press release9/10/2025, 5:00 AM

Neola Medical granted European patent enabling lung monitoring beyond preterm born babies

Press release8/26/2025, 12:26 PM

Redeye: Neola Medical Q2 - Potential share price trigger incoming

Regulatory press release8/25/2025, 5:55 AM

Neola Medical Q2 Report 2025 – First U.S. Clinical Study Site Agreement Signed, Key Step in Regulatory Path to Market Authorization

Press release8/18/2025, 5:00 AM

Neola Medical invites to presentation of the Q2-report 2025

Press release6/16/2025, 9:00 AM

Neola Medical’s CEO shares clinical progress and recent milestones in summer 2025 investor letter

Press release6/10/2025, 5:00 AM

Neola Medical Signs Agreement with Leading U.S. Hospital for Pivotal Clinical Study on Preterm Born Babies Following IRB Approval

Press release5/22/2025, 10:59 AM

Redeye: Neola Medical Q1 - Clinical progress on track

Regulatory press release5/21/2025, 6:45 AM

Neola Medical Q1 Report 2025 – Strengthened shareholder base with institutional investors ahead of clinical study start

Press release5/21/2025, 5:00 AM

First Patient Enrolled in Clinical Pilot Study with Neola® on Preterm Born Babies

Press release5/8/2025, 5:15 AM

Neola Medical Granted European Patent for Lung Monitoring, Strengthens Protection in Key Markets

Press release4/22/2025, 10:30 AM

Neola Medical named finalist for Sweden’s new global innovation award at World Expo 2025 in Japan

Regulatory press release4/9/2025, 9:45 AM

Neola Medical AB Publishes 2024 Annual Report

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.